ETIB Clinical Trials

今年，我们发表了第二阶段的结果，这表明孟鲁司特可以安全地停止 闭塞性细支气管炎综合征的进展， 造血细胞移植后慢性移植物抗宿主病（cGVHD）。中 在一项合作研究中，我们发现在一个队列中， 成人cGVHD患者多因素Logistic回归模型显示， 在这项研究中，一组因素与肌肉骨骼症状中度相关。在 此外，我们发现IFN基因抑制可持久缓解临床和血清学症状 在难治性系统性红斑狼疮（SLE）中， 自体造血细胞移植（AHSCT）。

This year we published our phase II results, that suggest montelukast may safely halt the progression of bronchiolitis obliterans syndrome which is a severe manifestation of chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation. In a collaborative study, we found a high frequency of musculoskeletal symptoms in a cohort of adult patients with cGVHD. The multivariable logistic regression models showed that a joint set of factors were moderately well associated with musculoskeletal symptoms in this study. In addition, we found durable clinical and serologic remissions with suppression in the IFN gene signature can be achieved in refractory systemic lupus erythematosus (SLE) following lymphodepleting autologous haematopoietic cell transplantation (AHSCT).